The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
Tocilizumab Promising for sJIA
In a clinical trial of pediatric patients, tocilizumab proved safe and effective for treating systemic juvenile idiopathic arthritis…
Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology
In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…
Parents Give Back after Watching Daughter’s Struggle with Systemic Juvenile Idiopathic Arthritis
Diagnosis prompts Steve and Debbie Russell to support the Rheumatology Research Foundation
ACR Issues sJIA Recommendations, SSc Classification Criteria
Guidelines address advances in pathophysiology and treatment of systemic juvenile idiopathic arthritis; criteria classify broader spectrum of systemic sclerosis
Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis
In patients with simultaneous systemic and arthritic components of systemic juvenile idiopathic arthritis (SJIA), these components appear to be related mechanistically. Moreover, the inflammatory pathways of SJIA appear to be distinct from those seen in polyarticular JIA.